comparemela.com

Latest Breaking News On - Research at gilead - Page 3 : comparemela.com

Gilead And EVOQ Ink Deal Worth up to $685M For Autoimmune Diseases

Gilead Sciences and EVOQ have announced a potential $685M collaboration around autoimmune disease.

United statesFoster cityFlavius martinWilliam brinkerhoffGilead sciencesResearch at gileadDentritic cellExecutive vice presidentJounce therapeutics

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential .

Foster cityUnited statesFlavius martinExchange commissionGilead sciencesTherapeutics incResearch at gileadGilead public affairsGilead sciences incLicense exclusive worldwide rightsInvestigational candidateHave optionsLicense several additionalDragonfly therapeuticsDragonfly tri specificInvestigational new drug

Flavius Martin | Gilead

Flavius Martin description

Flavius martinDivision of developmentalResearch at gileadUniversity of medicineResearch biology at amgenCardiometabolic researchUniversity of alabama at birminghamExecutive vice presidentVice presidentResearch biologyAmgen south sanPharmacy timisoaraபிரிவு ஆஃப் வளர்ச்சிஆராய்ச்சி இல் கிலியட்பல்கலைக்கழகம் ஆஃப் மருந்துகார்டியோமெட்டபாலிக் ஆராய்ச்சி

vimarsana © 2020. All Rights Reserved.